Porownywarka
Tirzepatide vs Setmelanotide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Tirzepatide | Setmelanotide |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | Mounjaro, Zepbound, LY3298176 | Imcivree, RM-493 |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea
| FDA approved for specified rare obesity indications including BBS, POMC/PCSK1/LEPR deficiency, and acquired hypothalamic obesity.
|
| Czego oczekiwac | Weight loss, diabetes management, metabolic health | Genetic obesity disorders and rare metabolic conditions |
| Jak dziala | Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved. | Setmelanotide is reported as a melanocortin-4 receptor agonist. The supplied mechanism evidence places MC4R downstream of leptin and POMC signaling in hypothalamic appetite regulation. For rare conditions such as POMC, PCSK1, or LEPR deficiency, the source states that upstream signaling can be impaired while MC4R remains a target; direct MC4R agonism is therefore presented as the rationale for its narrow genetic-obesity use. |
| Typowe dawkowanie | 5-15 mg weekly (after titration) · Once weekly | 2-3 mg daily · Once daily · Subcutaneous injection |
| Dawkowanie z badań | 2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly | 2-3 mg daily in adults · Long-term / chronic use · Subcutaneous injection daily |
| Typowy czas trwania | Long-term / chronic use | Long-term / chronic use |
| Podanie | Subcutaneous injection weekly | Subcutaneous injection |
| Timing | Morning, same day each week With or without food | Beginning of the day Without regard to meals |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+9 więcej
|
+4 więcej
|
| Podsumowanie researchu | The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results. | The supplied source summarizes clinical evidence as narrow but strong for rare disease populations. It reports pivotal open-label, single-arm phase 3 studies in POMC and LEPR deficiency, with at least 10% weight loss at about one year in 80% of POMC participants and 45% of LEPR participants, plus reduced hunger scores. The source also cites a randomized placebo-controlled phase 3 study for Bardet-Biedl syndrome and a 2024 VENTURE open-label study including children as young as two. Because the conditions are rare, the evidence base is described as small and indication-specific rather than broadly applicable to common obesity. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.